MX2023014582A - Fabricacion de agentes de contraste dimericos. - Google Patents

Fabricacion de agentes de contraste dimericos.

Info

Publication number
MX2023014582A
MX2023014582A MX2023014582A MX2023014582A MX2023014582A MX 2023014582 A MX2023014582 A MX 2023014582A MX 2023014582 A MX2023014582 A MX 2023014582A MX 2023014582 A MX2023014582 A MX 2023014582A MX 2023014582 A MX2023014582 A MX 2023014582A
Authority
MX
Mexico
Prior art keywords
sup
îon
contrast agents
manufacturing
îoo
Prior art date
Application number
MX2023014582A
Other languages
English (en)
Spanish (es)
Inventor
Federica Buonsanti
Valeria Boi
Sonia Gazzetto
Andrea Banin
Andrea Barale
Original Assignee
Bracco Imaging Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging Spa filed Critical Bracco Imaging Spa
Publication of MX2023014582A publication Critical patent/MX2023014582A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023014582A 2021-07-27 2022-07-26 Fabricacion de agentes de contraste dimericos. MX2023014582A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21187883 2021-07-27
PCT/EP2022/070901 WO2023006721A1 (en) 2021-07-27 2022-07-26 Manufacturing of dimeric contrast agents

Publications (1)

Publication Number Publication Date
MX2023014582A true MX2023014582A (es) 2023-12-13

Family

ID=77367218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014582A MX2023014582A (es) 2021-07-27 2022-07-26 Fabricacion de agentes de contraste dimericos.

Country Status (13)

Country Link
US (1) US12290576B2 (cg-RX-API-DMAC7.html)
EP (1) EP4377323B1 (cg-RX-API-DMAC7.html)
JP (1) JP7774081B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240034693A (cg-RX-API-DMAC7.html)
CN (1) CN117412980A (cg-RX-API-DMAC7.html)
AU (1) AU2022317221A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022921A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216972A1 (cg-RX-API-DMAC7.html)
ES (1) ES3041651T3 (cg-RX-API-DMAC7.html)
IL (1) IL308888A (cg-RX-API-DMAC7.html)
MX (1) MX2023014582A (cg-RX-API-DMAC7.html)
PL (1) PL4377323T3 (cg-RX-API-DMAC7.html)
WO (1) WO2023006721A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991736T3 (es) * 2020-07-27 2024-12-04 Bracco Imaging Spa Fabricación de agentes de contraste diméricos
AU2022318032A1 (en) * 2021-07-27 2023-12-21 Bracco Imaging Spa Process for the manufacturing of a gadolinium complex solution

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009119A1 (de) * 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4035760A1 (de) * 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
IT1291624B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
DE19849465A1 (de) 1998-10-21 2000-04-27 Schering Ag Dimere Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
IT1304501B1 (it) * 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
PL3753929T3 (pl) 2015-12-10 2023-03-13 Bracco Imaging Spa Dimeryczne środki kontrastowe
IL293806B1 (en) * 2019-12-13 2026-05-01 Bracco Imaging Spa Production of protected DO3A salts

Also Published As

Publication number Publication date
EP4377323A1 (en) 2024-06-05
CN117412980A (zh) 2024-01-16
AU2022317221A1 (en) 2023-11-16
IL308888A (en) 2024-01-01
CA3216972A1 (en) 2023-02-02
PL4377323T3 (pl) 2025-12-01
EP4377323C0 (en) 2025-07-02
KR20240034693A (ko) 2024-03-14
ES3041651T3 (en) 2025-11-13
US12290576B2 (en) 2025-05-06
WO2023006721A1 (en) 2023-02-02
BR112023022921A2 (pt) 2024-02-27
US20240269330A1 (en) 2024-08-15
JP7774081B2 (ja) 2025-11-20
JP2024527691A (ja) 2024-07-26
EP4377323B1 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
Moi et al. The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-nitrobenzyl)-1, 4, 7, 10-tetraazacyclododecane-N, N', N", N'''-tetraacetic acid and study of its yttrium (III) complex
Brendza et al. Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice
Ahmad et al. An essential role for katanin in severing microtubules in the neuron
Sasaki et al. Synergic effects of rehabilitation and intravenous infusion of mesenchymal stem cells after stroke in rats
Schäbitz et al. Neuroprotection by hyperbaric oxygenation after experimental focal cerebral ischemia monitored by MRI
Murakami et al. Experimental brain injury induces expression of amyloid precursor protein, which may be related to neuronal loss in the hippocampus
US10328162B1 (en) CEST systems exhibiting a concentration independent responsiveness
NZ315997A (en) Method of diagnosing alzheimers' disease by quantitating p97 in a sample from a patient
EP2055797A1 (en) Iron-based alloy and process for producing the same
Lucassen et al. Activation of the human supraptic and paraventricular nucleus neurons with aging and in Alzheimer's disease as judged from increasing size of the Golgi apparatus
US11110185B2 (en) Combination formulation
BR112023000078A2 (pt) Fabricação de agentes de contraste diméricos
WO2002094191A2 (en) Detection of alzheimer's amyloid by magnetic resonance imaging
IL163937A (en) Contrast agents for magnetic resonance imaging and methods related thereto
BR112023022921A2 (pt) Fabricação de agentes de contraste diméricos
US10393736B2 (en) Anti-fouling saline and siloxane coated particles, substrates, polymers and uses related thereto
TW522270B (en) Ferrule having optical fiber incorporated therein as an integral part thereof and method for production thereof
ATE522230T1 (de) Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit
Ciallella et al. Heat shock alters Alzheimer's β amyloid precursor protein expression in human endothelial cells
WO2006099516A3 (en) Methods for magnetic resonance imaging
MX2023014518A (es) Proceso para la fabricacion de una disolucion de complejo de gadolinio.
US20230218781A1 (en) Methods for triggering m1 macrophage polarization
US20230067910A1 (en) Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
EP0431167B1 (en) Production method of soft magnetic steel material
Marra et al. Effect of magnetic resonance imaging on implantable eyelid weights